10-Q: FOXO Technologies Secures $750,000 Loan and Reports Q1 2024 Results Amidst Financial Challenges

FOXO Technologies secured a $750,000 loan while reporting a net loss of $2.16 million for Q1 2024, highlighting ongoing financial difficulties and strategic shifts.

Summary

• FOXO Technologies secured a promissory note for up to $750,000 from ClearThink Capital Partners, with an initial purchase price of $500,000 and a 12% interest rate, maturing on January 30, 2025.
• The company reported a net loss to common stockholders of $2.16 million for the quarter ended March 31, 2024, compared to a $7.64 million loss in the same period of 2023.
• Revenue decreased to $7,000 from $13,000 year-over-year, primarily due to reduced royalty revenue in FOXO Labs and lower life insurance commissions in FOXO Life.
• Operating expenses decreased significantly to $1.19 million from $7.41 million, driven by lower consulting, employee, and legal expenses.
• The company's cash and cash equivalents stood at $3,000 as of March 31, 2024, down from $38,000 at the end of 2023.
• A deemed dividend of $656,000 was recorded due to the trigger of down round provisions and the extension of Assumed Warrants.
• The company is facing potential delisting from the NYSE American due to non-compliance with listing standards, including a failure to file its annual report on time and outstanding listing fees.
• FOXO is pursuing strategic acquisitions, including agreements with Rennova Health, to improve its financial position.
• The company has a working capital deficit of $16.81 million and an accumulated deficit of $14.94 million as of March 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern without securing additional capital.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including low cash reserves, substantial losses, and potential delisting. While there are some positive developments, such as reduced operating expenses and strategic acquisitions, the overall sentiment is negative due to the company's precarious financial position and going concern uncertainty.

Positives

• The net loss improved significantly year-over-year, decreasing from $7.64 million to $2.16 million.
• Operating expenses were substantially reduced, indicating cost-cutting measures are taking effect.
• The company secured a $750,000 loan, providing some short-term financial relief.
• FOXO is actively pursuing strategic acquisitions, which could provide a path to improved financial stability.

Negatives

• Revenue decreased to $7,000 from $13,000 year-over-year, indicating weak sales performance.
• The company's cash balance is critically low at $3,000, raising concerns about its ability to fund operations.
• FOXO is facing potential delisting from the NYSE American due to non-compliance with listing standards.
• The company has a significant working capital deficit of $16.81 million and an accumulated deficit of $14.94 million.
• There is substantial doubt about the company's ability to continue as a going concern without securing additional capital.

Risks

• The company's low cash balance poses a significant risk to its ability to continue operations.
• Failure to regain compliance with NYSE American listing standards could result in delisting.
• The company's ability to secure additional financing is uncertain.
• The company is in default of its Senior PIK Notes, which could lead to acceleration of debt.
• The company is in default of a settlement agreement with Smithline, which could lead to further legal action.
• The company's ability to generate sufficient revenue to cover its operating expenses is uncertain.

Future Outlook

The company expects to continue to incur operating losses and is dependent on securing additional capital through equity or debt financings and strategic acquisitions to fund its operations. The company believes it can fund operations until the end of the fourth quarter of 2024, assuming the stock exchange agreements are successful.

Management Comments

• Management is focused on commercializing scientific discoveries in health and longevity.
• Management believes there is value in the biomarkers they are developing.
• Management is strategically extending its expertise in epigenetic data processing and analysis to outside parties.
• Management is pursuing additional avenues to capitalize the company, including strategic operating companies.

Industry Context

The company is operating in the emerging field of epigenetic biomarker technology, which is gaining traction in the health and longevity sectors. The company's focus on AI and machine learning aligns with broader industry trends in data-driven healthcare solutions. However, the company faces significant competition and financial challenges in this space.

Comparison to Industry Standards

• The company's revenue of $7,000 for the quarter is significantly lower than many comparable biotech and health tech companies, which often report revenues in the millions.
• The company's cash balance of $3,000 is critically low compared to industry standards, where companies typically maintain a cash runway of at least 12 months.
• The company's net loss of $2.16 million, while improved year-over-year, is still substantial and indicates a need for significant operational improvements.
• The company's reliance on debt financing and strategic acquisitions to stay afloat is not uncommon for early-stage biotech companies, but the level of financial distress is concerning.
• The company's potential delisting from the NYSE American is a significant negative compared to industry peers that maintain compliance with listing standards.
• Comparable companies in the epigenetic space, such as companies focused on methylation analysis, often have more established revenue streams and stronger financial positions.

Management Changes

Legal Proceedings

• The company is in default of a settlement agreement with Smithline Family Trust II, which could lead to further legal action.
• The company is party to various other legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business.

Related Party Transactions

• The company's Interim CEO and Interim CFO are equity owners of KR8, with whom the company has a license agreement.
• The company has a loan from a former director, Andrew J. Poole.
• The company has related party payables to the Sponsor.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential delisting.
• Employees may be impacted by potential layoffs or restructuring due to the company's financial challenges.
• Customers may be affected by potential disruptions in service or product availability.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company must regain compliance with NYSE American listing standards to avoid delisting.
• The company needs to successfully close the stock exchange agreements with Rennova Health.
• The company needs to improve its revenue generation and reduce its losses.
• The company needs to resolve the default on its Senior PIK Notes and the settlement agreement with Smithline.

Key Dates

Keywords

FOXO Technologies, Promissory Note, ClearThink Capital Partners, Q1 2024 Results, Financial Loss, NYSE American, Delisting, Strategic Acquisitions, Epigenetic Biomarkers, Going Concern